Skip to main content

Table 3 Diagnostic performance and complications

From: Diagnostic performance of endoscopic ultrasound-guided tissue acquisition by EUS-FNA versus EUS-FNB for solid pancreatic mass without ROSE: a retrospective study

Variables EUS-FNA (n = 77) EUS-FNB (n = 74) P value
Adequate tissue reported by a pathologist, n (%) 57 (74) 74 (100) < 0.001
Diagnostic yield, n (%)    
 Overall 69 (89.6) 70 (94.6) 0.406
 In mass size < 4 cm 39/47 (83) 40/43 (93) 0.146
 In mass size > 4 cm 30/30 (100) 30/31 (96.8) 1
Diagnosis following EUS-TA, n (%)    0.232
 Pancreatic adenocarcinoma 40 (51.9) 52 (70.3)  
 Pancreatic neuroendocrine tumour 8 (10.4) 5 (6.8)  
 Mass forming chronic pancreatitis 10 (13) 3 (4.1)  
 Pancreatic lymphoma 4 (5.2) 3 (4.1)  
 Pancreatic tuberculosis 2 (2.6) 1 (1.4)  
 Other diseases 5 (6.5) 6 (8.1)  
 Non-diagnostic 8 (10.4) 4 (5.4)  
Severe adverse event, n (%) 0 (0) 1 (0.7) 0.49
Stage of disease in patient with pancreatic cancer (AJCC), n (%) N = 40 N = 52 0.087
 I 1 (2.5) 1 (1.9)  
 II 8 (20) 3 (5.8)  
 III 21 (52.5) 26 (50)  
 IV 10 (25) 22 (42.3)